Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Functional Impairment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

NCT02442258
View directory record Official record
Conditions
Renal Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

NCT04831944
View directory record Official record
Conditions
Advanced Malignancies
Interventions
parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Rialto, California • Tustin, California • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

NCT05724693
View directory record Official record
Conditions
Healthy Volunteer, Hepatic Impairment
Interventions
Bemnifosbuvir (BEM)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

NCT07248839
View directory record Official record
Conditions
Healthy Volunteers, Hepatic Impairment
Interventions
BMS-986435
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

NCT01392807
View directory record Official record
Conditions
Hepatic; Functional Disturbance
Interventions
NKTR-118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rhythmically Entrained Exercise in Community-Dwelling Older Adults

NCT05462977
View directory record Official record
Conditions
Exercise, Gait, Cognitive Decline, Caregiver Burden, Cognitive Impairment, Dementia, Alzheimer Disease, Mild Cognitive Impairment, Respite Care, Mental Health, Depression, Music Therapy, Psychosocial Intervention, Cognition, Geriatric Assessment, Cognitive Dysfunction, Cognitive Aging, Outcome Assessment, Health Care, Balance, Fall, Walking, Affect, Physical Exertion, Memory Deficit, Memory Disorders, Memory Impairment, Neuropsychological Tests, Executive Function, Middle Aged, Healthy Aging, Elderly
Interventions
Group exercise program
Behavioral
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
55 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

NCT01443481
View directory record Official record
Conditions
Solid Tumors, Hepatic Impairment
Interventions
Dovitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

NCT07342881
View directory record Official record
Conditions
Chronic Hepatitis B Infection
Interventions
Pevifoscorvir Sodium (ALG-000184)
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational

Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias

NCT00654251
View directory record Official record
Conditions
Spinocerebellar Ataxia
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Jackson, Mississippi • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

NCT03890770
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

NCT01331941
View directory record Official record
Conditions
Advanced Solid Tumors, Kidney Disease, Renal Impairment
Interventions
AMG 386 + Paclitaxel, AMG 386
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

NCT01351753
View directory record Official record
Conditions
Obesity, Metabolic Syndrome X
Interventions
Metformin, Orlistat, Topiramate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

NCT06723535
View directory record Official record
Conditions
Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions
BMS-986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function

NCT06698549
View directory record Official record
Conditions
COVID 19
Interventions
ALG-097558
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in People With Renal Impairment

NCT07034768
View directory record Official record
Conditions
Renal Impairments
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function

NCT00094965
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Oxaliplatin (SR96669)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2009 · Synced Sep 22, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

NCT01278758
View directory record Official record
Conditions
Metastatic Cancer
Interventions
ASA404, DMXAA or DXAA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Indianapolis, Indiana • Rockville, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

NCT01367509
View directory record Official record
Conditions
Renal Impairment
Interventions
Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 22, 2026, 4:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

rTMS to Improve Cognition in Parkinson's

NCT03836950
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

NCT00775684
View directory record Official record
Conditions
Pre-diabetes, Type 2 Diabetes
Interventions
Exenatide, Sitagliptin, Glimepiride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

NCT01575925
View directory record Official record
Conditions
Multiple Myeloma, Renal Impairment
Interventions
4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Not applicable Interventional

The Mental Activity and eXercise Trial for Seniors

NCT00522899
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Group 1, Group 2, Group 3, Group 4
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2012 · Synced Sep 22, 2026, 4:37 AM EDT
Completed No phase listed Observational Results available

Diaphragm Pacing in Individuals With Spinal Cord Injuries

NCT04179799
View directory record Official record
Conditions
Cervical Spinal Cord Injury
Interventions
Diaphragm Pacing
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 22, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

NCT05624723
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 22, 2026, 4:37 AM EDT